

ONCOSEC MEDICAL Inc
Form 10-Q
March 08, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NO. 000-54318

ONCOSEC MEDICAL INCORPORATED

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

NEVADA **98-0573252**
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

24 NORTH MAIN STREET
PENNINGTON, NJ **08534**
(Address of principal executive offices) (Zip Code)

3565 GENERAL ATOMICS COURT, SUITE 100 92121
SAN DIEGO, CA

(855) 662-6732

(Registrant's telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act.]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
 No

The number of shares outstanding of the Registrant's Common Stock, \$0.0001 par value, was 64,793,769 as of March 8, 2019.

OncoSec Medical Incorporated

Form 10-Q

for the Quarterly Period Ended January 31, 2019

PART I—FINANCIAL INFORMATION

Item 1. <u>Financial Statements:</u>	3
a) <u>Condensed Consolidated Balance Sheets as of January 31, 2019 (unaudited) and July 31, 2018</u>	3
b) <u>Condensed Consolidated Statements of Operations for the three and six months ended January 31, 2019 and 2018 (unaudited)</u>	4
c) <u>Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended January 31, 2019 and 2018 (unaudited)</u>	5
d) <u>Condensed Consolidated Statements of Cash Flows for the six months ended January 31, 2019 and 2018 (unaudited)</u>	6
e) <u>Notes to Condensed Consolidated Financial Statements (unaudited)</u>	7
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	25
Item 3. <u>Quantitative and Qualitative Disclosures about Market Risk</u>	33
Item 4. <u>Controls and Procedures</u>	33
<u>PART II—OTHER INFORMATION</u>	34
Item 1. <u>Legal Proceedings</u>	34
Item 1A. <u>Risk Factors</u>	34
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	34
Item 3. <u>Defaults Upon Senior Securities</u>	34
Item 4. <u>Mine Safety Disclosures</u>	34
Item 5. <u>Other Information</u>	34
Item 6. <u>Exhibits</u>	35
<u>SIGNATURES</u>	36

PART I—FINANCIAL INFORMATION**Item 1. Financial Statements:****OncoSec Medical Incorporated****Condensed Consolidated Balance Sheets**

	January 31, 2019 (unaudited)	July 31, 2018
Assets		
Current assets		
Cash and cash equivalents	\$24,487,265	\$3,803,627
Prepaid expenses and other current assets	1,988,631	1,643,749
Investment securities	4,241,413	23,174,447
Total Current Assets	30,717,309	28,621,823
Property and equipment, net	1,143,921	1,265,662
Other long-term assets	362,918	358,987
Total Assets	\$32,224,148	\$30,246,472
Liabilities and Stockholders' Equity		
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities	\$4,454,068	\$4,778,892
Accrued compensation and related	2,089,572	1,070,744
Total Current Liabilities	6,543,640	5,849,636
Other long-term liabilities	1,011,426	1,472,630
Total Liabilities	7,555,066	7,322,266
Commitments and Contingencies (Note 8)		
Stockholders' Equity		
Common stock authorized - 160,000,000 common shares with a par value of \$0.0001, common stock issued and outstanding — 64,621,352 and 53,511,626 common shares as of January 31, 2019 and July 31, 2018, respectively	6,463	5,351
Additional paid-in capital	163,417,084	145,744,373
Warrants issued and outstanding - 8,928,905 and 8,958,059 warrants as of January 31, 2019 and July 31, 2018, respectively	11,171,166	11,271,327
Accumulated other comprehensive income (loss)	45,833	(16,024)

Edgar Filing: ONCOSEC MEDICAL Inc - Form 10-Q

Accumulated deficit	(149,971,464)	(134,080,821)
Total Stockholders' Equity	24,669,082	22,924,206
Total Liabilities and Stockholders' Equity	\$32,224,148	\$30,246,472

The accompanying notes are an integral part of these condensed consolidated financial statements.

OncoSec Medical Incorporated**Condensed Consolidated Statements of Operations****(Unaudited)**

	Three Months Ended		Six Months Ended	
	January 31, 2019	January 31, 2018	January 31, 2019	January 31, 2018
Revenue	\$-	\$-	\$-	\$-
Expenses:				
Research and development	4,746,530	2,994,937	9,485,975	6,408,086
General and administrative	3,733,408	5,290,096	6,497,497	7,804,135
Loss from operations	(8,479,938)	(8,285,033)	(15,983,472)	(14,212,221)
Other income, net	105,903	15,279	220,305	42,015
Foreign currency exchange gain (loss), net	63,912	-	(108,002)	-
Realized loss on sale of securities, net	-	-	(12,134)	-
Warrant inducement expense	-	(2,465,396)	-	(2,465,396)
Loss before income taxes	(8,310,123)	(10,735,150)	(15,883,303)	(16,635,602)
Provision for income taxes	4,904	951	7,340	951
Net loss	\$(8,315,027)	\$(10,736,101)	\$(15,890,643)	\$(16,636,553)
Basic and diluted net loss per common share	\$(0.13)	\$(0.31)	\$(0.27)	\$(0.58)
Weighted average shares used in computing basic and diluted net loss per common share	62,726,254	34,794,004	58,960,310	28,561,809

The accompanying notes are an integral part of these condensed consolidated financial statements.

OncoSec Medical Incorporated

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

	Three Months Ended		Six Months Ended	
	January 31, 2019	January 31, 2018	January 31, 2019	January 31, 2018
Net Loss	\$(8,315,027)	\$(10,736,101)	\$(15,890,643)	\$(16,636,553)
Foreign currency translation adjustments	(46,043)	30,610	61,857	23,865
Comprehensive Loss	\$(8,361,070)	\$(10,705,491)	\$(15,828,786)	\$(16,612,688)

The accompanying notes are an integral part of these condensed consolidated financial statements.

OncoSec Medical Incorporated**Condensed Consolidated Statements of Cash Flows****(Unaudited)**

	Six Months Ended	
	January 31, 2019	January 31, 2018
Operating activities		
Net loss	\$(15,890,643)	\$(16,636,553)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	121,741	190,973
Loss on disposal of property and equipment, net	-	15,498
Warrant inducement expense	-	2,465,396
Amortization of discount on investments	(42,893)	-
Stock-based compensation	2,304,108	2,981,509
Common stock issued for services	445,611	843,250
Modification of equity award	135,425	-
Foreign currency exchange loss, net	108,002	-
Changes in operating assets and liabilities:		
Prepaid expenses and other current assets	(340,425)	(308,123)
Other long-term assets	(8,051)	(4,042)
Accounts payable and accrued liabilities	(618,005)	(846,318)
Accrued compensation	1,018,826	46,286
Other long-term liabilities	(461,205)	37,756
Net cash used in operating activities	(13,227,509)	(11,214,368)
Investing activities		
Purchases of property and equipment	-	(8,213)
Maturity of investment securities	12,986,000	-
Sale of investment securities	5,977,794	-
Net cash provided by (used in) investing activities	18,963,794	(8,213)
Financing activities		
Proceeds from issuance of common stock through ESPP	23,390	19,048
Proceeds from issuance of common stock and/or warrants	15,000,000	9,283,443
Payment of financing and offering costs	(573,189)	(1,396,531)
Proceeds from exercise of options	566,135	157,928
Proceeds from exercise of warrants	-	9,593,733
Tax withholdings paid on equity awards	(50,640)	-
Tax withholdings paid related to net share settlement of equity awards	(32,505)	-
Tax shares sold to pay for tax withholdings on equity awards	40,243	-
Net cash provided by financing activities	14,973,434	17,657,621
Effect of exchange rate changes on cash and cash equivalents	(26,081)	23,865
Net increase in cash and cash equivalents	20,683,638	6,458,905
Cash and cash equivalents, at beginning of period	3,803,627	11,444,676

Edgar Filing: ONCOSEC MEDICAL Inc - Form 10-Q

Cash and cash equivalents, at end of period	\$24,487,265	\$17,903,581
Supplemental disclosure for cash flow information:		
Cash paid during the period for:		
Interest	\$-	\$-
Income taxes	\$1,700	\$951
Noncash investing and financing transactions:		
Expiration of warrants	\$100,162	\$1,200,742
Amounts accrued for offering costs	\$304,916	\$-

The accompanying notes are an integral part of these condensed consolidated financial statements.

OncoSec Medical Incorporated

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Note 1—Nature of Operations and Basis of Presentation

The Company is a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. Its core platform technology, ImmunoPulse®, is a drug-device therapeutic modality comprised of a proprietary intratumoral electroporation delivery device. The ImmunoPulse® platform is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse® device can be adapted to treat different tumor types, and consists of an electrical pulse generator, a reusable handle and disposable applicators. The Company's lead product candidate is a DNA-encoded interleukin-12 ("IL-12"), called tavokinogene telseplasmid ("TAVO"). The ImmunoPulse® electroporation platform is used to deliver TAVO intratumorally, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The activation of the appropriate inflammatory response can drive a systemic anti-tumor response against untreated tumors in other parts of the body. In February 2017, the Company received Fast Track designation from the U.S. Food and Drug Administration ("FDA") for TAVO in metastatic melanoma, which could qualify TAVO for expedited FDA review, a rolling Biologics License Application review and certain other benefits.

The Company's current focus is to pursue its study of TAVO in combination with KEYTRUDA® (pembrolizumab) in melanoma, cervical, and triple negative breast cancer ("TNBC").

KEYNOTE-695 targets melanoma patients who are definitive anti-PD-1 non-responders. In May 2017, the Company entered into a clinical trial collaboration and supply agreement with a subsidiary of Merck & Co., Inc. ("Merck") in connection with the KEYNOTE-695 study. This study is a registration-directed, Phase 2b open-label, single-arm, multicenter study in the United States, Canada and Australia. Pursuant to the terms of the agreement, both companies will bear their own costs related to manufacturing and supply of their product, as well as be responsible for their own internal costs. The Company will sponsor the study and be responsible for external costs.

KEYNOTE-695 is currently enrolling and treating patients and the Company provided topline preliminary data updates at The Society for Immunotherapy of Cancer ("SITC") in November of 2018 and at its Business Outlook in February 2019. The Company does not plan to provide any further data updates regarding KEYNOTE-695. Based upon the preliminary patient tumor evaluations and responses previously observed, the Company plans to focus on completing enrollment with respect to KEYNOTE-695, as well as other requisite activities necessary to prepare to file

for accelerated approval in the United States and file for regulatory approval in Europe for TAVO in conjunction with pembrolizumab in the treatment of patients with unresectable or metastatic melanoma and disease progression following anti-PD-1 therapy and, if BRAF V600 mutation positive, a BRAF inhibitor.

OMS-150 targets women with recurrent/persistent cervical cancer. In December 2018, we entered into a collaboration with the Gynecologic Oncology Group (“GOG”) Foundation, the world-renowned, non-profit organization with the purpose of conducting clinical research for the prevention and treatment of all gynecologic cancers, including cervical cancer. OMS-150 will evaluate the combination of TAVO and commercially available KEYTRUDA®. We plan to begin enrollment in 2019. This study is a registration-directed, Phase 2b open-label, single-arm, multicenter study.

The Company is also pursuing development in TNBC. In May 2018, the Company entered into a second clinical trial collaboration and supply agreement with Merck with respect to a Phase 2 study of TAVO in combination with KEYTRUDA® to evaluate the safety and efficacy of the combination in patients with inoperable locally advanced or metastatic TNBC, who have previously failed at least one systemic chemotherapy or immunotherapy. This study is referred to as KEYNOTE-890. Pursuant to the terms of the agreement, both companies will bear their own costs related to manufacturing and supply of their product, as well as be responsible for their own internal costs. The Company will sponsor the study and be responsible for external costs. The KEYNOTE-890 study is currently enrolling and treating patients. The study is a Phase 2 open-label, single-arm, multicenter study in the United States and Australia.

The Company intends to continue to pursue other ongoing or potential new trials and studies related to TAVO, in various tumor types. In addition, the Company is also developing its next-generation electroporation device and applicator, including advancements toward prototypes, pursuing discovery research to identify other product candidates that, in addition to IL-12, can be encoded into propriety plasmid-DNA, delivered intratumorally using electroporation. Using the Company's next-generation technology, its goal is to reverse the immunosuppressive mechanisms of a tumor, as well as to expand its ImmunoPulse® pipeline. The Company believes that the flexibility of its propriety plasmid-DNA technology allows it to deliver other immunologically relevant molecules into the tumor microenvironment in addition to the delivery of plasmid-DNA encoding for IL-12. In March 2019, the Company will have a poster presentation at the 2019 America Association for Cancer Research ("AACR") where it will present pre-clinical data regarding its new anti-tumor product candidate, which will amplify the power of intratumoral IL-12 through the addition of both CXCL9, a critical T cell chemokine, and anti-CD3, a membrane bound pan T cell stimulator. These other immunologically relevant molecules may compliment IL-12's activity by limiting or enhancing key pathways associated with tumor immune subversion.

Basis of Presentation

In October 2016, the Company created an Australian corporation as its wholly-owned subsidiary. This corporation's functional currency, the Australian dollar, is also its reporting currency, and its financial statements are translated to U.S. dollars, the Company's reporting currency, prior to consolidation. The accompanying condensed consolidated financial statements include the accounts of the Company and its subsidiary, and all intercompany accounts and transactions have been eliminated in consolidation.

Unaudited Interim Financial Information

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of January 31, 2019, the condensed consolidated statements of operations and the condensed consolidated statements of comprehensive loss for the three and six months ended January 31, 2019 and 2018, and the condensed consolidated statements of cash flows for the six months ended January 31, 2019 and 2018, are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the Company's financial position, results of operations and cash flows for the periods presented. The condensed consolidated results of operations for the three and six months ended January 31, 2019 shown herein are not necessarily indicative of the consolidated results that may be expected for the year ending July 31, 2019, or for any other period. These condensed consolidated financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the fiscal year ended July 31, 2018, included in the Company's Annual Report on Form 10-K (the "Annual Report") filed with the U.S. Securities and Exchange Commission ("SEC") on October 19, 2018. The condensed consolidated balance sheet at July 31, 2018 has been derived from the audited

financial statements at that date but does not include all the information and footnotes required by U.S. GAAP for complete financial statements.

Note 2—Significant Accounting Policies

Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Such estimates include stock-based compensation, accounting for long-lived assets and accounting for income taxes, including the related valuation allowance on the deferred tax asset and uncertain tax positions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. On an ongoing basis, the Company reviews its estimates to ensure that they appropriately reflect changes in the business or as new information becomes available. Actual results could differ materially from these estimates.

Segment Reporting

The Company operates in a single industry segment—the discovery and development of novel immunotherapeutic product candidates to improve treatment options for patients and physicians, intended to treat a wide range of oncology indications.

Cash and Cash Equivalents

The Company considers all highly liquid investments that are readily convertible into cash and have an original maturity of three months or less at the time of purchase to be considered cash equivalents.

Concentrations and Credit Risk

The Company maintains cash balances at a small number of financial institutions and such balances commonly exceed the \$250,000 amount insured by the Federal Deposit Insurance Corporation. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant credit risk with respect to such cash and cash equivalents.

Investment Securities

Securities held to maturity are recorded at amortized cost based on the Company's positive intent and ability to hold these securities to maturity.

Management evaluates whether securities held to maturity are other-than-temporarily impaired ("OTTI") on a quarterly basis. Debt securities with unrealized losses are considered OTTI if the Company intends to sell the security or if it is more likely than not that the Company will be required to sell such security prior to any anticipated recovery. If management determines that a security is OTTI under these circumstances, the impairment recognized in earnings is measured as the entire difference between the amortized cost and the then-current fair value.

Property and Equipment

The Company's capitalization threshold is \$5,000 for property and equipment. The cost of property and equipment is depreciated on a straight-line basis over the estimated useful lives of the related assets. The useful lives of property and equipment for the purpose of computing depreciation are as follows:

Computers and equipment: 3 to 10 years
Computer software: 1 to 3 years
Leasehold improvements: Shorter of lease period or useful life

Impairment of Long-Lived Assets

The Company periodically assesses the carrying value of intangible and other long-lived assets, and whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. The assets are considered to be impaired if the Company determines that the carrying value may not be recoverable based upon its assessment, which includes consideration of the following events or changes in circumstances:

the asset's ability to continue to generate income from operations and positive cash flow in future periods;

loss of legal ownership or title to the asset;

significant changes in the Company's strategic business objectives and utilization of the asset(s); and

the impact of significant negative industry or economic trends.

If the assets are considered to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets. Fair value is determined by the application of discounted cash flow models to project cash flows from the asset. In addition, the Company bases estimates of the useful lives and related amortization or depreciation expense on its subjective estimate of the period the assets will generate revenue or otherwise be used by it. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less selling costs. The Company also periodically reviews the lives assigned to long-lived assets to ensure that the initial estimates do not exceed any revised estimated periods from which the Company expects to realize cash flows from its assets.

Fair Value of Financial Instruments

The carrying amounts for cash, prepaid expenses, accounts payable and accrued expenses approximate fair value due to the short-term nature of these instruments. It is management's opinion that the Company is not exposed to significant interest, currency, or credit risks arising from its other financial instruments and that their fair values approximate their carrying values except where expressly disclosed.

The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company's principal or, in absence of a principal, most advantageous market for the specific asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.

The three tiers are defined as follows:

Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. The Company's Level 1 assets consist of bank deposits and money market funds.

Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. The Company's Level 2 assets consist of U.S.

government sponsored securities.

Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company's Chief Financial Officer.

Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.

No such items existed as of January 31, 2019 and July 31, 2018.

Financial Instruments Not Recorded at Fair Value

Descriptions of the valuation methodologies and assumptions used to estimate the fair value of financial instruments not recorded at fair value are described below. The Company's financial instruments not recorded at fair value but for which fair value can be approximated and disclosed include:

Securities Held to Maturity – The fair values of securities held to maturity are obtained using an independent third-party financial institution.

Warrants

The Company assesses its warrants as either equity or a liability based upon the characteristics and provisions of each instrument. Warrants classified as equity are recorded at fair value as of the date of issuance on the Company's balance sheet and no further adjustments to their valuation are made. Warrants classified as derivative liabilities and other derivative financial instruments that require separate accounting as liabilities are recorded on the Company's balance sheet at their fair value on the date of issuance and are re-measured on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using option pricing models and assumptions that are based on the individual characteristics of the warrants or other instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield and risk-free interest rate. As of January 31, 2019 and July 31, 2018, all outstanding warrants issued by the Company were classified as equity.

Net Loss Per Share

The Company computes basic net loss per common share by dividing the applicable net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing the applicable net loss by the weighted-average number of common shares outstanding during the period plus additional shares to account for the dilutive effect of potential future issuances of common stock relating to stock options and other potentially dilutive securities using the treasury stock method.

The Company did not include shares underlying stock options, restricted stock units and warrants issued and outstanding during any of the periods presented in the computation of net loss per share, as the effect would have been anti-dilutive. The following potentially dilutive outstanding securities were excluded from diluted net loss per share

because of their anti-dilutive effect:

	For the Three and Six Months Ended	For the Three and Six Months Ended
	January 31, 2019	January 31, 2018
Stock options	9,148,309	7,278,625
Restricted stock units	1,138,541	1,100,000
Warrants	8,928,905	9,283,059
Total	19,215,755	17,661,684

Stock-Based Compensation

The Company grants equity-based awards (typically stock options or restricted stock units) under our stock-based compensation plan and outside of our stock-based compensation plan, with terms generally similar to the terms under our stock-based compensation plan. The Company estimates the fair value of stock option awards using the Black-Scholes option valuation model. For employees, directors and consultants, the fair value of the award is measured on the grant date. Prior to the adoption of ASU 2018-07 on August 1, 2018, the fair value of the award for non-employees was generally re-measured on vesting dates and interim financial reporting dates until the service period was complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. The Company estimates the fair value of restricted stock unit awards based on the closing price of the Company's common stock on the date of issuance. Changes in assumptions used under the Black-Scholes option valuation model could materially affect the Company's net loss and net loss per share.

Employee Stock Purchase Plan

Employees may elect to participate in the Company's stockholder approved employee stock purchase plan. The stock purchase plan allows for the purchase of the Company's common stock at not less than 85% of the lesser of (i) the fair market value of a share of common stock on the beginning date of the offering period or (ii) the fair market value of a share of common stock on the purchase date of the offering period, subject to a share and dollar limit as defined in the plan and subject to the applicable legal requirements. There are two six-month offering periods during each fiscal year, ending on January 31 and July 31.

In accordance with applicable accounting guidance, the fair value of awards under the stock purchase plan is calculated at the beginning of each offering period. The Company estimates the fair value of the awards using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and the offering period. This fair value is then amortized at the beginning of the offering period. Stock-based compensation expense is based on awards expected to be purchased at the beginning of the offering period, and therefore is reduced when participants withdraw during the offering period.

Deferred Rent

Rent expense from leases is recorded on a straight-line basis over the lease period. The net excess of rent expense over the actual cash paid is recorded as deferred rent.

Foreign Currency Translation

We use the U.S. Dollar as the reporting currency for our financial statements. Functional currency is the currency of the primary economic environment in which an entity operates. The functional currency of our wholly owned subsidiary is the Australian dollar.

Assets and liabilities of our subsidiary are translated into U.S. Dollars at period-end foreign exchange rates, and revenues and expenses are translated at average rates prevailing throughout the period. Translation adjustments are included in "Accumulated other comprehensive income (loss)," a separate component of stockholders' equity, and in the "Effect of exchange rate changes on cash and cash equivalents," on our condensed consolidated statements of cash flows. Transaction gains and losses including intercompany transactions denominated in a currency other than the

functional currency of the entity involved are included in “Foreign currency exchange gain (loss), net” on our condensed consolidated statements of operations.

Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income (loss) includes foreign currency translation adjustments related to the Company’s subsidiary in Australia and is excluded from the accompanying condensed consolidated statements of operations.

Australia Research and Development Tax Credit

The Company’s wholly-owned Australian subsidiary incurs research and development expenses, primarily in the course of conducting clinical trials. The Company’s Australian research and development activities qualify for the Australian government’s tax credit program, which provides a 41.0 percent credit for qualifying research and development expenses. The tax credit does not depend on the Company’s generation of future taxable income or ongoing tax status or position. Accordingly, the credit is not considered an element of income tax accounting under ASC 740 and is recorded against qualifying research and development expenses.

Tax Reform

The Tax Cuts and Jobs Act (the “Act”) was enacted in December 2017. Among other things, the Act reduced the U.S. federal corporate tax rate from 34 percent to 21 percent as of January 1, 2018 and eliminated the alternative minimum tax (“AMT”) for corporations. Since the deferred tax assets are expected to reverse in a future year, it has been tax effected using the 21% federal corporate tax rate. As a result of the reduction in the corporate tax rate, the Company decreased its gross deferred tax assets by approximately \$12.4 million which was offset by a corresponding decrease to the valuation allowance as of July 31, 2018, which had no impact on the Company’s consolidated financial statements for the year ended July 31, 2018. The effects of the 2017 Tax Act did not have a significant impact on the Company’s unaudited condensed consolidated financial statements for the three and six months ended January 31, 2019.

Recent Accounting Pronouncements

In January 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2016-01, *Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities* (“ASU 2016-01”), which addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. ASU 2016-01 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those annual periods, and earlier adoption is not permitted except for certain provisions. The Company adopted this standard on August 1, 2018. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures.

In August 2016, the FASB issued ASU No. 2016-15, *Statement of Cash Flows* (“ASU 2016-15”), to reduce diversity in practice of how certain transactions are classified in the statement of cash flows. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted this standard on August 1, 2018. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures.

In January 2017, the FASB issued guidance codified in ASU 2017-04, *Intangibles—Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment* (“ASU 2017-04”). Under this guidance, an entity will no longer determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Instead, an entity will compare the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods therein, with early adoption permitted. The Company adopted this standard on August 1, 2018. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures. The Company does

not currently have any intangible or goodwill balances.

In May 2017, the FASB issued ASU 2017-09, *Compensation—Stock Compensation (Topic 718)* (“ASU 2017-09”), which provides further guidance as to what constitutes a modification to the terms of share-based compensation, in order to create consistency in practice among all entities. ASU 2017-09 becomes effective for annual reporting periods beginning after December 15, 2017, including interim periods thereafter; early adoption is permitted. The Company adopted this standard on August 1, 2018. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures.

In July 2017, the FASB issued ASU 2017-11, *Earnings Per Share (Topic 260), Distinguishing Equity from Liabilities (Topic 480) and Derivatives and Hedging (Topic 815)* (“ASU 2017-11”), which addresses the complexity of accounting for certain financial instruments with down-round features and finalizes pending guidance related to mandatorily redeemable noncontrolling interests. Under ASU 2017-11, when determining whether certain financial instruments should be classified as liabilities or equity instruments, a down-round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. ASU 2017-11 becomes effective for annual reporting periods beginning after December 15, 2018, including interim periods thereafter; early adoption is permitted. The Company adopted this standard on August 1, 2018. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures.

In June 2018, the FASB issued ASU 2018-07, *“Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting”* (ASU 2018-07), which expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which the grantor acquires goods and services to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted, but no earlier than our adoption of ASC 606. The Company chose to early adopt ASU 2018-07 on August 1, 2018. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and related disclosures.

There were no accounting pronouncements during the six months ended January 31, 2019 that the Company anticipates will have a material impact on the Company’s financial condition, results of operations or related disclosures. See Note 2 to the Annual Report for a discussion of certain recent accounting pronouncements not yet adopted by the Company.

Note 3—Liquidity and Financial Condition

The Company has sustained losses in all reporting periods since inception, with an inception-to-date loss of \$150.0 million as of January 31, 2019, which raises substantial doubt. Further, the Company has never generated any cash from its operations and does not expect to generate such cash in the near term. Consequently, the Company will need additional capital to continue operating its business and fund its planned operations, including research and development, clinical trials and, if regulatory approval is obtained, commercialization of its product candidates. In addition, the Company will require additional financing if it desires to in-license or acquire new assets, research and develop new compounds or new technologies and pursue related patent protection, or obtain any other intellectual property rights or other assets.

As of January 31, 2019, the Company had cash, cash equivalents and investment securities of \$28.7 million. The Company had cash of \$9.8 million and cash equivalents of \$14.7 million for a total cash and cash equivalents balance of \$24.5 million. In addition, the Company had short-term investment securities of \$4.2 million. Cash flows from financing activities continued to provide the primary source of our liquidity. Net cash provided by financing activities was \$15.0 million during the six months ended January 31, 2019, which was primarily attributable to the net proceeds received from the Alpha Holdings agreement and the exercise of certain stock options (See Note 6).

The Company is anticipating raising additional capital but there can be no assurance that it will be able to do so or if the terms will be favorable. As of the date of the issuance of these condensed consolidated financial statements, the Company believes its current cash position as a result of the Company's financing activities during the six months ended January 31, 2019 has alleviated substantial doubt about its ability to sustain operations through at least the next 12 months from the issuance date of the condensed consolidated financial statements.

Note 4—Investment Securities

The amortized cost, gross unrealized losses, and fair value of securities held to maturity are as follows as of January 31, 2019:

Description	Amortized Cost	Gross	Gross	Fair Value
		Unrealized Gains	Unrealized Loss	
Investment securities				
U.S. treasury securities with maturities of one year or less	\$4,241,413	\$ -	\$ (2,233)	\$4,239,180
Total	\$4,241,413	\$ -	\$ (2,233)	\$4,239,180

The fair values of held to maturity securities, excluding U.S. treasury securities, were obtained using an independent third-party financial institution. Management made no adjustments to the fair value quotes that were provided by the third-party financial institution. The fair values of U.S. treasury securities were determined using quoted, active market prices for identical securities.

During the six months ended January 31, 2019, the Company sold investments, categorized as held to maturity, with a net carrying amount of \$5,989,928 for gross proceeds of \$5,977,794 and realized a loss of \$0 and \$12,134 during the three and six months ended January 31, 2019, respectively. The sale of the securities was suggested by the Company's investment advisors and the event is isolated.

Note 5—Balance Sheet Details*Property and Equipment*

Property and equipment, net, is comprised of the following:

January 31,	July 31,
2019	2018

Edgar Filing: ONCOSEC MEDICAL Inc - Form 10-Q

Equipment and furniture	\$1,873,880	\$1,873,880
Computer software	109,242	109,242
Leasehold improvements	12,054	12,054
Property and equipment, gross	1,995,176	1,995,176
Accumulated depreciation and amortization	(851,255)	(729,514)
Total	\$1,143,921	\$1,265,662

Depreciation and amortization expense recorded for the three and six months ended January 31, 2019 was approximately \$61,000 and \$122,000, respectively. Depreciation and amortization expense recorded for the three and six months ended January 31, 2018 was approximately \$95,000 and \$191,000, respectively.

Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities are comprised of the following:

	January 31, 2019	July 31, 2018
Research and development costs	\$2,726,710	\$3,801,211
Professional services fees	1,466,329	770,853
Other	261,029	206,828
Total	\$4,454,068	\$4,778,892

Accrued Compensation

Accrued compensation is comprised of the following:

	January 31, 2019	July 31, 2018
Separation costs	\$978,289	\$840,320
Accrued payroll	1,099,996	215,937
401K payable	11,287	14,487
Total	\$2,089,572	\$1,070,744

Other Long-Term Liabilities

Other long-term liabilities are comprised of the following:

	January 31, 2019	July 31, 2018
Deferred rent	\$872,940	\$1,101,222
Separation costs	138,486	371,408
Total	\$1,011,426	\$1,472,630

Note 6—Stockholders' Equity

A summary of the changes in stockholders' equity for the six months ended January 31, 2019 and 2018 is presented below:

	January 31, 2019	January 31, 2018
Stockholders' equity at beginning of period	\$22,924,206	\$10,695,982
Net loss	(15,890,643)	(16,636,553)
Stock-based compensation	2,304,108	2,981,509
Common stock issued for services	445,611	843,250
Modification of equity award	135,425	-

Edgar Filing: ONCOSEC MEDICAL Inc - Form 10-Q

Issuance of common stock through employee stock purchase plan	23,390	19,048
Equity offerings, net of costs	14,141,895	7,886,913
Accumulated other comprehensive income (loss)	61,857	23,865
Exercise of common stock warrants	-	9,593,733
Exercise of common stock options	566,135	157,928
Inducement warrant issuance	-	2,465,396
Tax withholdings paid on equity awards	(50,640)	-
Tax shares sold to pay for tax withholdings on equity awards	40,243	-
Tax withholdings paid related to net share settlement of equity awards	(32,505)	-
Stockholders' equity at end of period	\$24,669,082	\$18,031,071

Alpha Holdings

On August 31, 2018, the Company entered into a stock purchase agreement with Alpha Holdings, Inc. (“Alpha Holdings”), pursuant to which the Company agreed to issue and sell to Alpha Holdings shares of its common stock equal to an aggregate amount of up to \$15.0 million at a market purchase price of \$1.50 per share, which was the closing price of the Company’s common stock the day immediately before the agreement was executed by the parties.

On October 8, 2018, the Company received total proceeds, before expenses, of \$8.0 million in cash from the offering and issued Alpha Holdings 5,333,333 shares of common stock at a purchase price of \$1.50 per share. There were no underwriting or placement agent fees associated with the offering.

On December 6, 2018, the Company received total proceeds, before expenses, of \$7.0 million in cash from the offering and issued Alpha Holdings 4,666,667 shares of common stock at a purchase price of \$1.50 per share. There were no underwriting or placement agent fees associated with the offering.

Controlled Equity Offering Sales Agreement

On November 2, 2018, the Company entered into a controlled equity offering sales agreement (“Sales Agreement”) with Cantor Fitzgerald & Co, regarding an at-the-market offering, pursuant to which the Company may, from time to time, issue and sell shares of common stock having an aggregate offering price of up to \$30.0 million. The Company is not obligated to make any sales of shares under the Sales Agreement. To date, the Company has not made any sales of shares under the Sales Agreement.

Common Stock Option Exercise

During the six months ended January 31, 2019, shares of common stock issued related to option exercises totaled 430,293. The Company realized proceeds of \$0.6 million from the stock option exercises.

November 2017 Warrant Exercise Inducement Offering

On November 13, 2017, the Company entered into a warrant exercise agreement with certain holders of outstanding warrants (the “Original Warrants”) to purchase up to an aggregate of 5,509,642 shares of the Company’s common stock at an exercise price of \$1.69 per share. Pursuant to the terms of the warrant exercise agreement, each holder agreed to exercise, from time to time and in accordance with the terms of the Original Warrants, including certain beneficial ownership limitations set forth therein, all Original Warrants held by it for cash. As a result of the exercise of all of the Original Warrants, the Company received gross proceeds of approximately \$9.3 million and net proceeds, after deducting estimated expenses paid or payable by the Company, of approximately \$9.1 million.

Pursuant to the terms of the warrant exercise agreement, and in order to induce each holder to exercise its Original Warrants, the Company issued 1,377,411 new warrants to purchase a number of shares of its common stock which is equal to 25% of the number of shares of common stock received by such holders upon the cash exercise of its Original Warrants. The terms of the inducement warrants are substantially similar to the terms of the Original Warrants, except that the inducement warrants: (i) have an initial exercise price of \$2.26 per share; (ii) become exercisable on May 13, 2018 and expire on November 13, 2019; and, (iii) contain certain additional transfer restrictions and limitations due to

their offer and sale in a private placement offering.

Also on November 13, 2017, and in connection with its entry into the warrant exercise agreement, the Company agreed to issue warrants to purchase up to an aggregate of 1,138,300 shares of its common stock to the accredited investors that participated in the Company's offerings completed in October 2017, in consideration for such investors agreement to waive certain covenants made by the Company to such investors and as an inducement to such investors to exercise certain other warrants to purchase the Company's common stock. The terms of the October 2017 investor warrants are substantially similar to the terms of the new warrants, except that the October 2017 investor warrants will become exercisable only if and when each October 2017 investor exercises in full and for cash the warrants to purchase the Company's common stock that were sold to such investors in the Company's offerings completed in October 2017.

The warrants issued in connection with the warrant exercise agreement were considered inducement warrants and are classified in equity. The fair value of the warrants issued was approximately \$2.5 million (based on the Black-Scholes option valuation model assuming no dividend yield, a 2.0-year life, volatility of 73.12% and a risk-free interest rate of 1.7%). The fair value of the inducement warrants of \$2.5 million was expensed as warrant inducement expense in the accompanying condensed consolidated statement of operations for the three and six months ended January 31, 2018.

First October 2017 Offering

On October 25, 2017, the Company completed an offer and sale to certain accredited investors of, in a registered public offering, 5,270,934 shares of its common stock and, in a concurrent private placement offering, warrants to purchase an aggregate of up to 3,953,200 shares of its common stock, all at a purchase price of \$1.34375 per share. The warrants have an initial exercise price of \$1.25 per share, became exercisable on October 25, 2017 and expire on April 25, 2022. The gross proceeds of the offering were \$7.1 million and the net proceeds, after deducting the placement agent's fee and other offering fees and expenses paid or payable by the Company (and excluding the proceeds, if any, from any cash exercise of the warrants), were approximately \$6.2 million. In connection with the offering, the Company paid the placement agent (i) a cash fee equal to 5.5% of the gross proceeds of the offering, as well as offering expenses in a nonaccountable sum of \$60,000, and (ii) warrants to purchase up to an aggregate of 316,256 shares of its common stock. The warrants issued to the placement agent are exercisable at an exercise price of \$1.68 per share, became exercisable on their original issuance date and expire on October 21, 2022.

The fair value of the warrants issued to the purchasers in the offerings, based on their fair value relative to the common stock issued, was approximately \$2.4 million (based on the Black-Scholes option valuation model assuming no dividend yield, a 5.5-year life, volatility of 75.55% and a risk-free interest rate of 2.12%). The fair value of the warrants issued to the placement agent in the offerings was \$0.2 million (based on the Black-Scholes option valuation model assuming no dividend yield, a 5.0-year life, volatility of 73.25% and a risk-free interest rate of 2.06%). The Company completed an evaluation of these warrants and determined they should be classified as equity within the accompanying condensed consolidated balance sheets.

Second October 2017 Offering

On October 25, 2017, the Company completed an offer and sale to one accredited investor of 800,000 shares of its common stock and warrants to purchase up to 600,000 shares of its common stock, all at a purchase price of \$1.34375 per share and associated warrant. The warrants have an initial exercise price of \$1.25 per share, become exercisable on April 27, 2018 and expire on April 27, 2022. The gross proceeds of the offering were \$1.1 million and the net proceeds, after deducting the placement agent's fee and other offering fees and expenses paid or payable by the Company (and excluding the proceeds, if any, from any cash exercise of the warrants), were approximately \$1.0 million. In connection with the offering, the Company paid the placement agent (i) a cash fee equal to 5.5% of the gross proceeds of the offering, as well as offering expenses in a non-accountable sum of \$15,000, and (ii) warrants to purchase up to an aggregate of 48,000 shares of its common stock. The warrants issued to the placement agent are exercisable at an exercise price of \$1.68 per share, became exercisable on their original issuance date and expire on October 25, 2022.

The fair value of the warrants issued to the purchasers in the offering, based on their fair value relative to the common stock issued, was approximately \$0.4 million (based on the Black-Scholes option valuation model assuming no dividend yield, a 5.5-year life, volatility of 75.51% and a risk-free interest rate of 2.12%). The fair value of the warrants issued to the placement agent in the offering was \$31,000 (based on the Black-Scholes option valuation model assuming no dividend yield, a 5.0-year life, volatility of 73.22% and a risk-free interest rate of 2.06%). The Company completed an evaluation of these warrants and determined they should be classified as equity within the accompanying condensed consolidated balance sheets.

ATM Program

On July 25, 2017, the Company entered into an equity distribution agreement with Oppenheimer & Co. Inc. (“Oppenheimer”) to commence an “at the market” offering program (the “ATM Program”), under which the Company was permitted to offer and sell, from time to time through or to Oppenheimer, acting as sales agent or principal, shares of the Company’s common stock having an aggregate gross sales price of up to \$8.4 million. An aggregate of 897,311 shares of the Company’s common stock were sold in the ATM Program during the six months ended January 31, 2018, for net proceeds to the Company, after deducting Oppenheimer’s commissions and other expenses paid or payable by the Company, of \$1.1 million. Effective as of October 22, 2017, the Company terminated the ATM Program. As a result of such termination, no further offers or sales of the Company’s common stock will be made in the ATM Program.

Outstanding Warrants

At January 31, 2019, the Company had outstanding warrants to purchase 8,928,905 shares of its common stock, with exercise prices ranging from \$1.25 to \$18.00, all of which were classified as equity instruments. These warrants expire at various dates between May 2019 and April 2023.

Note 7—Stock-Based Compensation

The OncoSec Medical Incorporated 2011 Stock Incentive Plan (as amended and approved by the Company's stockholders (the "2011 Plan")), authorizes the Company's Board of Directors to grant equity awards, including stock options and restricted stock units, to employees, directors and consultants. The 2011 Plan authorizes a total of 7,500,000 for issuance thereunder, and includes an automatic increase of the number of shares of common stock reserved thereunder on the first business day of each calendar year by the lesser of: (i) 3% of the shares of the Company's common stock outstanding as of the last day of the immediately preceding calendar year; (ii) 1,000,000 shares; or (iii) such lesser number of shares as determined by the Company's Board of Directors. As of January 31, 2019, there were an aggregate of 9,500,000 shares of the Company's common stock authorized for issuance pursuant to awards granted under the 2011 Plan. The 2011 Plan allows for an annual fiscal year per individual grant of up to 500,000 shares of its common stock. Under the 2011 Plan, incentive stock options are to be granted at a price that is no less than 100% of the fair value of the Company's common stock at the date of grant. Stock options vest over a period specified in the individual option agreements entered into with grantees, and are exercisable for a maximum period of 10 years after the date of grant. Stock options granted to stockholders who own more than 10% of the outstanding stock of the Company at the time of grant must be issued at an exercise price of no less than 110% of the fair value of the Company's common stock on the date of grant.

Modification of Award

On August 22, 2018, the Company entered into a stock option cancellation agreement with an individual. As per the terms of the agreement, 300,000 fully vested stock options were cancelled. On August 22, 2018, the Company issued 175,000 shares of restricted common stock. Upon modification, it is required under ASC 718 to analyze the fair value of the instruments, before and after the modification, recognizing the increase as a charge to the statement of operations. The Company computed the fair value of the cancelled award and compared the fair value to that of the restricted stock award. The Company recorded the excess of the fair value of the restricted stock award over the fair value of the cancelled award, or \$135,425, to compensation costs with an offsetting entry to common stock and additional paid in capital on the date of the modification.

Cancellation of Award

On October 23, 2018, the Company entered into stock option cancellation agreements with two consultants. As per the terms of the agreements, an aggregate of 535,000 stock options were cancelled. The consultants were not issued replacement awards under the cancellation agreements. Under ASC 718, a cancellation of an award that is not accompanied by the concurrent grant of (or offer to grant) a replacement award or other valuable consideration shall be accounted for as a repurchase for no consideration. Accordingly, any previously unrecognized compensation cost shall be recognized at the cancellation date. The Company recorded unrecognized compensation of the cancelled awards, or \$377,278, to compensation costs with an offsetting entry to additional paid in capital on the date of the cancellation.

Stock Options

During the six months ended January 31, 2019, the Company granted options to purchase 1,241,000 and 675,000 shares of its common stock to employees and directors under the 2011 Plan, respectively. The stock options issued to employees have a ten-year term, vest over three years, and have exercise prices ranging from \$0.6001 to \$1.58. The stock options issued to directors have a 10-year term, vest over a period ranging from one to three years and have exercise prices ranging from \$0.655 and \$0.8412.

During the six months ended January 31, 2019, the Company granted options to purchase 200,000 and 500,000 shares of its common stock to employees and consultants outside the 2011 Plan. The stock options issued to employees have a ten-year term, vest over three years, and have an exercise price of \$1.64. The stock options issued to consultants have ten-year terms, vest in accordance with the terms of the applicable consulting agreement and have exercise prices ranging from \$0.8461 and \$1.43.

During the six months ended January 31, 2018, the Company granted options to purchase 933,500, 450,000 and 125,000 shares of its common stock to employees, directors and consultants under the 2011 Plan, respectively. The stock options issued to employees have a 10-year term, vest over three years and have exercise prices ranging from \$0.92 and \$1.32. The stock options issued to directors have a 10-year term, vest over one year and have exercise prices ranging from \$0.979 and \$1.94. The stock options issued to consultants have a 10-year term, vest in accordance with the terms of the applicable consulting agreement and have exercise prices ranging from \$1.00 and \$1.32.

During the six months ended January 31, 2018, the Company granted its President and Chief Executive Officer, Mr. Daniel J. O'Connor, options to purchase 2,500,000 shares of the Company's common stock outside of the 2011 Plan. This grant was approved by stockholders at the Company's annual meeting on January 12, 2018. Of the total grant, options on 1,000,000 shares vested upon stockholder approval and options on 1,000,000 shares will vest over a two-year period from the date of grant. Mr. O'Connor also received a performance stock option award to purchase up to 500,000 shares of the Company's common stock, which is subject to vesting as to options on 250,000 shares on the date of the Company's achievement of 100% enrollment in the first cohort of its PISCES/KEYNOTE-695 study and as to the remaining options on 250,000 shares in one installment on the one-year anniversary of the date of achievement of such enrollment.

The Company accounts for stock-based compensation based on the fair value of the stock-based awards granted and records forfeitures as they occur. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants. The service period is generally the vesting period, with the exception of stock options granted pursuant to a consulting agreement, in which case the stock option vesting period and the service period are defined pursuant to the terms of the consulting agreement. Prior to the adoption of ASU 2018-07, stock-based compensation expense related to stock options granted to consultants in which the options were not entirely vested at the grant date were generally re-measured each month.

The following assumptions were used for the Black-Scholes calculation of the fair value of stock-based compensation related to stock options granted during the periods presented:

Six Months Ended	Six Months Ended
-----------------------------	-----------------------------

	January 31, 2019		January 31, 2018	
Expected term (years)	5.00 – 6.5 years		5.00 – 6.5 years	
Risk-free interest rate	2.47 – 3.09	%	1.66 – 2.43	%
Volatility	72.88 – 81.96	%	73.30 – 91.80	%
Dividend yield	0	%	0	%

The Company's expected volatility is derived from the historical daily change in the market price of its common stock since its stock became available for trading, as well as the historical daily changes in the market price of its peer group, based on weighting, as determined by the Company. The Company uses the simplified method to calculate the expected term of options issued to employees, non-employees and directors. Prior to the adoption of ASU 2018-07, the Company's estimation of the expected term for stock options granted to parties other than employees or directors was the contractual term of the option award. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield in effect at the time of grant, commensurate with the expected term. For the expected dividend yield used in the Black-Scholes calculation, the Company has never paid any dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future.

The following is a summary of the Company's 2011 Plan and non-Plan stock option activity for the six months ended January 31, 2019:

	Options	Weighted Average Exercise Price
Outstanding - July 31, 2018	8,912,720	\$ 1.50
Granted	2,616,000	\$ 0.86
Exercised	(430,293)	\$ 1.32
Forfeited/Cancelled	(1,943,118)	\$ 1.58
Expired	(7,000)	\$ 5.76
Outstanding – January 31, 2019	9,148,309	\$ 1.30
Exercisable – January 31, 2019	5,490,692	\$ 1.49

As of January 31, 2019, the total intrinsic value of options outstanding and exercisable was approximately \$425,000 and \$41,000, respectively. As of January 31, 2019, the Company has approximately \$3.0 million in unrecognized stock-based compensation expense attributable to the outstanding options, which will be amortized over a period of approximately 1.59 years.

Stock-based compensation expense recorded in the Company's condensed consolidated statements of operations for the three and six months ended January 31, 2019 resulting from stock options awarded to the Company's employees, directors and consultants was approximately \$1.1 million and \$2.9 million, respectively. Of this balance, \$0.25 million and \$1.1 million, respectively, was recorded to research and development and \$0.85 million and \$1.8 million, respectively, was recorded in general and administrative in the Company's condensed consolidated statements of operations for the three and six months ended January 31, 2019.

Stock-based compensation expense recorded in the Company's condensed consolidated statements of operations for the three and six months ended January 31, 2018 resulting from stock options awarded to the Company's employees, directors and consultants was approximately \$2.3 million and \$2.7 million, respectively. Of this balance, \$0.2 million and \$0.4 million, respectively, was recorded to research and development and \$2.1 million and \$2.3 million, respectively, was recorded in general and administrative in the Company's condensed consolidated statements of operations for the three and six months ended January 31, 2018.

The weighted-average grant date fair value of stock options granted during the three and six months ended January 31, 2019 was \$0.46 and \$0.57, respectively. The weighted-average grant date fair value of stock options granted during the three and six months ended January 31, 2018 was \$1.37 and \$1.29, respectively.

Restricted Stock Units

In December 2018, the Company granted its President and Chief Executive Officer 750,000 restricted stock unit awards (“RSUs”). The units vest as follows: 62,500 units vested on January 31, 2019, and the remaining 687,500 units vest in equal quarterly installments of 62,500 units beginning on April 30, 2019 and ending on October 31, 2021. The closing price of the Company’s common stock on the date of grant was \$0.6001 per share, which is the fair market value per unit of the RSUs.

In October 2018, the Company granted 50,000 RSUs to an employee. The units vest as follows: 12,500 units vested on October 29, 2018, and the remaining 37,500 units vest according to the following vesting schedule: 12,500 units on October 29, 2019, 12,500 units on October 29, 2020 and 12,500 units on October 29, 2021. The closing price of the Company’s common stock on the date of grant was \$1.64 per share, which is the fair market value per unit of the RSUs.

On October 26, 2018, in accordance with a severance agreement with an employee, the Company's Board of Directors approved the accelerated vesting of 25% of the outstanding RSUs held by the employee. The RSUs, which originally vest on the third anniversary of the grant date, or March 29, 2020, were accelerated to vest on October 26, 2018. As per ASC 718, on the date of the modification the Company reversed the previously accrued expense on the unvested RSUs of \$63,278 and recognized the fair value of the modified grant of \$44,250 on the date of the modification.

For the three and six months ended January 31, 2019, the Company recorded \$0.2 million and \$0.4 million in stock-based compensation related to RSUs, which is reflected in the condensed consolidated statement of operations.

As of January 31, 2019, there were 1,138,541 RSUs outstanding.

For the three and six months ended January 31, 2018, the Company recorded \$0.2 million and \$0.3 million, respectively, in stock-based compensation related to RSUs, which is reflected in the condensed consolidated statement of operations.

Shares Issued to Consultants

During the three and six months ended January 31, 2019, 143,000 and 327,000 shares of common stock valued at \$229,190 and \$480,750, respectively, were issued to consultants for services. The common stock share values were based on the dates the shares were granted. The Company recorded compensation expense relating to the share issuances of \$205,788 and \$449,348, respectively, during the three and six months ended January 31, 2019.

During the three and six months ended January 31, 2018, 375,000 and 475,000 shares of common stock valued at \$734,250 and \$843,250, respectively, were issued to consultants for services. The common stock share values were based on the dates the shares vested. The Company recorded compensation expense relating to the share issuances of \$734,250 and \$843,250, respectively, during the three and six months ended January 31, 2018.

2015 Employee Stock Purchase Plan

Under the Company's 2015 Employee Stock Purchase Plan ("ESPP"), the Company is authorized to issue 500,000 shares of the Company's common stock. The first offering period under the ESPP ended on July 31, 2016, with 17,789 shares

purchased and distributed to employees. The second offering period under the ESPP ended on January 31, 2017, with 18,631 shares purchased and distributed to employees, and the third offering period under the ESPP ended on July 31, 2017, with 21,646 shares purchased and distributed to employees. The fourth offering period under the ESPP ended on January 31, 2018, with 18,960 shares purchased and distributed to employees, and the fifth offering period under the ESPP ended on July 31, 2018, with 12,071 shares purchased and distributed to employees. The sixth offering period under the ESPP ended on January 31, 2019, with 14,287 shares purchased and distributed to employees. At January 31, 2019, there were 396,616 shares remaining available for issuance under the ESPP.

The ESPP is considered a Type B plan under FASB ASC Topic 718 because the number of shares a participant is permitted to purchase is not fixed based on the stock price at the beginning of the offering period and the expected withholdings. The ESPP enables the participant to “buy-up” to the plan’s share limit, if the stock price is lower on the purchase date. As a result, the fair value of the awards granted under the ESPP is calculated at the beginning of each offering period as the sum of:

15% of the share price of an unvested share at the beginning of the offering period,
85% of the fair market value of a six-month call on the unvested share aforementioned, and
15% of the fair market value of a six-month put on the unvested share aforementioned.

The fair market value of the six-month call and six-month put are based on the Black-Scholes option valuation model. For the six-month offering period ended January 31, 2019, the following assumptions were used: six-month maturity, 2.22% risk free interest, 61.83% volatility, 0% forfeitures and \$0 dividends.

For the six-month offering period ended January 31, 2018, the following assumptions were used: six-month maturity, 1.15% risk free interest, 62.6% volatility, 0% forfeitures and \$0 dividends.

Approximately \$6,500 and \$7,000 was recorded as stock-based compensation during the six months ended January 31, 2019 and 2018, respectively.

Common Stock Reserved for Future Issuance

The following table summarizes all common stock reserved for future issuance at January 31, 2019:

Common Stock options outstanding (within the 2011 Plan and outside of the terms of the 2011 Plan)	9,148,309
Common Stock reserved for restricted stock unit release	1,138,541
Common Stock authorized for future grant under the 2011 Plan	974,128
Common Stock reserved for warrant exercise	8,928,905
Commons Stock reserved for future ESPP issuance	396,616
Total common stock reserved for future issuance	20,586,499

Note 8—Commitments and Contingencies

Contingencies

In the ordinary course of business, the Company may become a party to lawsuits involving various matters. The Company is not currently a party, and its properties are not currently subject, to any legal proceedings that, in the opinion of management, are expected to have a material adverse effect on the Company's business, financial condition or results of operations.

Employment Agreements

The Company has entered into employment agreements with each of its executive officers and certain other key employees. Generally, the terms of these agreements provide that, if the Company terminates the officer or employee

other than for cause, death or disability, or if the officer terminates his or her employment with the Company for good cause, the officer shall be entitled to receive certain severance compensation and benefits as described in each such agreement.

On October 26, 2018, the Company and an employee entered into a separation and release agreement in connection with the employee's termination of employment with the Company. Pursuant to the agreement, the Company will pay the former employee severance compensation of \$415,000, less applicable withholdings, in the form of salary and bonus continuation in accordance with the Company's customary payroll practices. In addition, the Company agreed to pay the cost of health insurance for 12 months from the date of separation and accelerate the vesting of 25,000 RSUs. On October 26, 2018, the Company recorded a liability of \$451,112 on its condensed consolidated balance sheet, and the offsetting charge was recorded in research and development expense as salary expense.

Lease Agreements

On February 14, 2018, the Company entered into a lease agreement with MawIt Inc., for approximately 3,100 rentable square feet located at 24 N. Main Street, Pennington, New Jersey, which serves as the Company's New Jersey corporate headquarters. The term of the lease commenced on March 1, 2018 and was to expire on April 30, 2020. In November 2018, the Company entered into an amended lease agreement for the addition of approximately 2,800 rentable square feet. The term of the amended lease commenced on January 15, 2019 and expires on December 31, 2020. Base rent under the amended lease agreement is \$11,686 per month for each of the first two months, \$11,929 per month for each of the third through fifteenth months and \$12,173 per month for each of the sixteenth through twenty-three months. The Company prepaid rent of approximately \$60,000 as per the terms of the amended agreement. The lease agreement also requires the Company to share in certain monthly operating expenses of the premises and required the Company to pay a security deposit of \$23,372.

In March 2018, the Company entered into a lease assignment agreement (the “Lease Assignment Agreement”) with Vividion Therapeutics, Inc. (“Vividion”) for the Company’s 34,054 square foot location at 5820 Nancy Ridge Drive, San Diego, California, 92121 (“NR Premises”), whereby the Company assigned its lease agreement with ARE-SD Region No. 18, LLC (the “Landlord”) to Vividion. Under the Lease Assignment Agreement, Vividion pays directly to Landlord the base rent of \$101,500 per month (based upon \$2.98 per rentable square foot of the NR Premises) plus operating expenses and property management fees attributable to the NR Premises currently estimated at \$43,500 per month (including an estimate for utilities) during the term of the Lease Assignment Agreement, which is the remaining term of the lease through October 2025.

While the lease and all of the related obligations were assigned to Vividion, the Company could ultimately have an obligation on the Lease Assignment Agreement if Vividion defaulted on their obligation to the Landlord after all remedies were exhausted by the Landlord with regard to Vividion’s obligations. Such an event is not considered probable and no obligation has been recorded as of January 31, 2019 and July 31, 2018.

In conjunction with the Lease Assignment Agreement, the Company and Vividion also entered into a sublease (the “Sublease”), with respect to the 12,442 square-foot location at 3565 General Atomics Court, Suite 100, San Diego, CA, 92121 leased by Vividion from Landlord which serves as the Company’s California office (the “Sublease Premise”). Under the Sublease, the Company shall pay to Vividion base rent of \$49,768 per month subject to an annual 3% increase, (based upon \$4.00 per rentable square foot of the Sublease Premises) plus operating expenses and property management fees attributable to the Sublease Premises currently estimated at \$30,400 per month during the term of the Sublease, which extends through September 2020. The Company moved to the new location in April 2018.

At the time of the lease agreements noted above, the Company had a deferred rent liability recorded on the condensed consolidated balance sheet of \$1.1 million, which is being amortized on a straight-line basis over the term of the Sublease.

We have also entered into lease arrangements for vivarium space in San Diego, California to support our research and development department.

Total rent expense for the three months ended January 31, 2019 and 2018 was approximately \$199,000 and \$370,000, respectively. Total rent expense for the six months ended January 31, 2019 and 2018 was approximately \$413,000 and \$834,000, respectively.

We believe our current facilities are adequate to meet our current operating needs and will remain adequate for the foreseeable future. Should we need additional space, we currently do not foresee significant difficulties in obtaining

additional facilities.

Note 9—401(k) Plan

Effective May 15, 2012, the Company adopted a defined contribution savings plan pursuant to Section 401(k) of the Code. The plan is for the benefit of all qualifying employees and permits voluntary contributions by employees of up to 100% of eligible compensation, subject to the maximum limits imposed by Internal Revenue Service. The terms of the plan allow for discretionary employer contributions and the Company currently matches 100% of its employees' contributions, up to 3% of their annual compensation. The Company's contributions are recorded as expense in the accompanying condensed consolidated statements of operations and totaled approximately \$18,000 and \$45,000 for the three and six months ended January 31, 2019, respectively. The Company's contributions totaled approximately \$23,000 and \$48,000 for the three and six months ended January 31, 2018, respectively, respectively.

Note 10—Related Party Transactions

The Company subleased a portion of its office space to another company beginning April 1, 2017 and ending March 31, 2018. The Company's former President and two other members of the Company's Board of Directors held positions as directors and/or officers of the sublessee. The Company received payments totaling \$10,500 and \$19,500 related to the sublease during the three and six months ended January 31, 2018, respectively.

Note 11—Subsequent Events

Subsequent to January 31, 2019, shares of common stock issued to executives and employees related to vested RSU's totaled 90,417.

Subsequent to January 31, 2019, shares of common stock issued to consultants for services totaled 82,000.

Subsequent to January 31, 2019, the Company issued 10,000 stock options to a consultant as per the terms of an amendment to a consulting agreement.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Unless the context indicates otherwise, all references to "OncoSec," "our company," "we," "us" and "our" in this report refer to OncoSec Medical Incorporated and its consolidated subsidiary. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes included in this report.

This discussion and analysis of our financial condition and results of operations is not a complete description of our business or the risks associated with an investment in our common stock. As a result, this discussion and analysis should be read together with our condensed consolidated financial statements and related notes included in this report, as well as the other disclosures in this report and in the other documents we file from time to time with the Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K for our fiscal year ended July 31, 2018 filed with the SEC on October 19, 2018, or the Annual Report. Pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K promulgated by the SEC, in preparing this discussion and analysis, we have presumed that readers have access to and have read the discussion and analysis of our financial condition and results of operations included in the Annual Report.

This discussion and analysis and the other disclosures in this report contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act. Forward-looking statements relate to future events or circumstances or our future performance and are based on our current assumptions, expectations and beliefs about future developments and their potential effect on our business. All statements in this report that are not statements of historical fact could be forward-looking statements. The forward-looking statements in this discussion and analysis include statements about, among other things, the status, progress and results of our clinical programs and our expectations regarding our liquidity and performance, including our expense levels, sources of capital and ability to maintain our operations as a going concern. Forward-looking statements are only predictions and are not guarantees of future performance, and they are subject to known and unknown risks, uncertainties and other factors, including the risks described under the heading "Risk Factors" in Part I, Item IA of the Company's most recent Annual Report on Form 10-K and similar discussions contained in the other documents we file from time to time with the SEC. In light of these risks, uncertainties and other factors, the forward-looking events and circumstances described in this report may not occur and our results, levels of activity, performance or achievements could differ materially from those expressed in or implied by any forward-looking statements we make. As a result, you should not place undue reliance on any of our forward-looking statements. Forward-looking statements speak only as of the date they are made, and unless required to by law, we undertake no obligation to update or revise any forward-looking statement for any reason, including to reflect new information, future developments, actual results or changes in our expectations.

Overview

We are a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. Our core platform technology, ImmunoPulse®, is a drug-device therapeutic modality comprised of a proprietary intratumoral electroporation delivery device. The ImmunoPulse® platform is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse® device can be adapted to treat different tumor types, and consists of an electrical pulse generator, a reusable handle and disposable applicators. Our lead product candidate is a DNA-encoded interleukin-12 (“IL-12”), called tavokinogene telseplasmid (“TAVO”). The ImmunoPulse® electroporation platform is used to deliver TAVO intratumorally, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The activation of the appropriate inflammatory response can drive a systemic anti-tumor response against untreated tumors in other parts of the body. In February 2017, we received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for TAVO in metastatic melanoma, which could qualify TAVO for expedited FDA review, a rolling Biologics License Application review and certain other benefits.

We have completed monotherapy and combination programs and currently have ongoing clinical development programs with TAVO, in combination with checkpoint inhibitors in metastatic melanoma and triple negative breast cancer (“TNBC”). The Company intends to continue to pursue other ongoing or potential new trials and studies related to TAVO, in various tumor types. In addition, we are also developing our next-generation electroporation device and applicator, and are pursuing discovery research to identify other product candidates that, in addition to IL-12, can be encoded into propriety plasmid-DNA and delivered intratumorally using electroporation.

Performance Outlook

We expect to use our available working capital in the near term primarily for the advancement of our existing and planned clinical programs, including performance of the KEYNOTE-695 and KEYNOTE-890 studies and, to a lesser extent, the continuation of our other clinical trials and studies. We anticipate our spending on clinical programs and the development of our next-generation electroporation device for our ImmunoPulse® platform will continue throughout our current fiscal year, primarily in support of the KEYNOTE-695 and KEYNOTE-890 studies, while our spending on research and development programs will be prioritized, based on our focus on the KEYNOTE-695 and KEYNOTE-890 studies. We expect our cash-based general and administrative expenses to remain relatively flat in the near term, as we seek to continue to leverage internal resources and automate processes to decrease our outside services expenses. See “Results of Operations” below for more information.

Results of Operations for the Three Months Ended January 31, 2019 Compared to the Three Months Ended January 31, 2018

The unaudited financial data for the three months ended January 31, 2019 and January 31, 2018 is presented in the following table and the results of these two periods are included in the discussion thereafter.

	January 31, 2019	January 31, 2018	\$ Change	% Change
Revenue	\$-	\$-	-	-
Expenses				
Research and development	4,746,530	2,994,937	1,751,593	58
General and administrative	3,733,408	5,290,096	(1,556,688)	(29)
Loss from operations	(8,479,938)	(8,285,033)	194,905	2
Other income, net	105,903	15,279	(90,624)	(593)
Warrant inducement expense	-	(2,465,396)	(2,465,396)	(100)
Foreign currency exchange gain, net	63,912	-	(63,912)	(100)
Loss before income taxes	(8,310,123)	(10,735,150)	(2,425,027)	(23)

Provision for income taxes	4,904	951	3,953	416
Net loss	\$(8,315,027)	\$(10,736,101)	(2,421,074)	(23)

Revenue

We have not generated any revenue since our inception, and we do not anticipate generating meaningful, or any, revenue in the near term.

Research and Development Expenses

Our research and development expenses increased by approximately \$1.75 million, from \$3.0 million during the three months ended January 31, 2018 to \$4.75 million during the three months ended January 31, 2019. This increase was primarily due to the following approximate increases: (i) \$0.5 million in higher payroll and related-benefits expense, of which \$0.2 million was related to bonus expense, and (ii) \$1.4 million in clinical trial-related costs, inclusive of drug manufacturing needs, and product development costs to support our various clinical studies. These increases were partially offset by \$0.2 million decrease in lower facility rent costs due to moving to a new facility.

General and Administrative

Our general and administrative expenses decreased by approximately \$1.6 million, from \$5.3 million during the three months ended January 31, 2018 to \$3.7 million during the three months ended January 31, 2019. This decrease was primarily due to the following approximate decreases: (i) \$2.0 million in stock-based compensation expense primarily related to award cancellations and a decrease in the fair value of our stock; and (ii) \$0.2 million in payroll and related-benefits expense driven by a decrease in headcount, including two former executives. These decreases were partially offset by an increase of (i) \$0.3 million in general corporate and legal patent costs, and (ii) \$0.4 million in consulting and advisory services.

Other Income, Net

Other income, net, increased by approximately \$0.1 million during the three months ended January 31, 2019 as compared to the three months ended January 31, 2018. This increase was primarily due to higher balances on interest-bearing cash and marketable securities investment accounts.

Warrant Inducement Expense

The warrants issued during the three months ended January 31, 2018 in connection with our November 2017 warrant exercise inducement offering were considered inducement warrants and the fair value of the inducement warrants of \$2.5 million is classified as equity and expensed as warrant inducement expense

Foreign Currency Exchange Gain, Net

Foreign currency exchange gain, net, increased by approximately \$0.06 million during the three months ended January 31, 2019 as compared to the three months ended January 31, 2018. This increase was primarily due to unrealized foreign currency transaction gains recognized in connection with the Australian subsidiary's intercompany loan.

Results of Operations for the Six Months Ended January 31, 2019 Compared to the Six Months Ended January 31, 2018

The unaudited financial data for the six months ended January 31, 2019 and January 31, 2018 is presented in the following table and the results of these two periods are included in the discussion thereafter.

	January 31, 2019	January 31, 2018	\$ Change	% Change
Revenue	\$-	\$-	-	-
Expenses				
Research and development	9,485,975	6,408,086	3,077,889	48
General and administrative	6,497,497	7,804,135	(1,306,638)	(17)
Loss from operations	(15,983,472)	(14,212,221)	1,771,251	12
Other income, net	220,305	42,015	(178,290)	(424)
Warrant inducement expense	-	(2,465,396)	(2,465,396)	(100)
Foreign currency exchange loss, net	(108,002)	-	108,002	100
Realized loss on sale of securities, net	(12,134)	-	12,134	100
Loss before income taxes	(15,883,303)	(16,635,602)	(752,299)	(5)
Provision for income taxes	7,340	951	6,389	672
Net loss	\$(15,890,643)	\$(16,636,553)	(745,910)	(4)

Revenue

We have not generated any revenue since our inception, and we do not anticipate generating meaningful, or any, revenue in the near term.

Research and Development Expenses

Our research and development expenses increased by approximately \$3.1 million, from \$6.4 million during the six months ended January 31, 2018 to \$9.5 million during the six months ended January 31, 2019. This increase was primarily due to the following approximate increases: (i) \$1.2 million in higher payroll and related-benefits expense, of which \$0.2 million was related to bonus expense and \$0.4 million was related to severance expense; (ii) \$1.7 million in clinical trial-related costs, inclusive of drug manufacturing needs, and product development costs to support our various clinical studies, and (iii) \$0.6 million in stock-based compensation expense for employees and consultants. These increases were partially offset by \$0.4 million decrease in lower facility rent costs due to moving to a new facility.

General and Administrative

Our general and administrative expenses decreased by approximately \$1.3 million, from \$7.8 million during the six months ended January 31, 2018 to \$6.5 million during the six months ended January 31, 2019. This decrease was primarily due to the following approximate decreases: (i) \$1.6 million in stock-based compensation expense primarily related to award cancellations and a decrease in the fair value of our stock; (ii) \$0.4 million in payroll and related-benefits expense driven by a decrease in headcount, including two former executives, and (iii) \$0.1 million decrease in lower facility rent & utilities costs due to moving to a new facility. These decreases were partially offset by an increase of (i) \$0.4 million in general corporate and legal patent costs, and (ii) \$0.4 million in consulting and advisory services.

Other Income, Net

Other income, net, increased by approximately \$0.2 million during the six months ended January 31, 2019 as compared to the six months ended January 31, 2018. This increase was primarily due to higher balances on interest-bearing cash and marketable securities investment accounts.

Warrant Inducement Expense

The warrants issued during the six months ended January 31, 2018 in connection with our November 2017 warrant exercise inducement offering were considered inducement warrants and the fair value of the inducement warrants of \$2.5 million is classified as equity and expensed as warrant inducement expense

Foreign Currency Exchange Loss, Net

Foreign currency exchange loss, net, increased by approximately \$0.1 million during the six months ended January 31, 2019 as compared to the six months ended January 31, 2018. This increase was primarily due to unrealized foreign currency transaction losses recognized in connection with the Australian subsidiary's intercompany loan.

Liquidity and Capital Resources*Working Capital*

The following table and subsequent discussion summarize our working capital as of each of the periods presented:

	At	At
	January 31, 2019	July 31, 2018
Current assets	\$30,717,309	\$28,621,823
Current liabilities	6,543,640	5,849,636
Working capital	\$24,173,669	\$22,772,187

Current Assets

Current assets as of January 31, 2019 increased to \$30.7 million, from \$28.6 million as of July 31, 2018. This increase was primarily due to an increase in cash, cash equivalents and short-term investment securities from \$27.0 million as of July 31, 2018 to \$28.7 million as of January 31, 2019, which is attributable to the net proceeds received from our Alpha Holdings, Inc. stock purchase agreement and certain stock option exercises (see “Sources of Capital” below).

Current Liabilities

Current liabilities as of January 31, 2019 increased to \$6.5 million, from \$5.8 million as of July 31, 2018. This increase was primarily due to an increase in accrued compensation resulting from employee bonuses awarded in December 2018 and a severance accrual for a former employee. The increase was partially offset by lower accruals for non-recurring services for research and development costs.

Cash Flow

Cash Used in Operating Activities

Net cash used in operating activities for the six months ended January 31, 2019 was \$13.2 million, as compared to \$11.2 million for the six months ended January 31, 2018. The \$2.0 million increase in cash used in operating activities was primarily attributable to an increase in cash used to support our operating activities, including but not limited to, our clinical trials, an increase in R&D activities and general working capital requirements.

Cash Provided by (Used in) Investing Activities

Net cash provided by investing activities for the six months ended January 31, 2019 was \$19.0 million, as compared to net cash used in investing activities of \$8,000 for the six months ended January 31, 2018. The increase in cash provided by investing activities was related to maturities and sales of certain investment securities. We have an investment policy which is administered by management and reviewed by the Board of Directors. We believe our investment policy is conservative and maximizes returns, while minimizes risk, since we rely on the cash to fund operations.

Cash Provided by Financing Activities

Net cash provided by financing activities for the six months ended January 31, 2019 was \$15.0 million, as compared to \$17.7 million for the six months ended January 31, 2018. Net proceeds during the six months ended January 31, 2019 was primarily attributable to the net proceeds received from the Alpha Holdings offering. Net proceeds during the six months ended January 31, 2018 was primarily attributable to the net proceeds received from our October 2017 offerings and November 2017 warrant exercise inducement offerings (see “Sources of Capital” below).

Uses of Cash and Cash Requirements

Our primary uses of cash have been to finance clinical and research and development activities focused on the identification and discovery of new potential product candidates, the development of innovative and proprietary medical approaches for the treatment of cancer, and the design and advancement of pre-clinical and clinical trials and studies related to our pipeline of product candidates. We have also used our capital resources on general and administrative activities, including building and strengthening our corporate infrastructure, programs and procedures to enable compliance with applicable federal, state and local laws and regulations.

Our primary objectives for the next 12 months are to continue the advancement of our KEYNOTE-695 and KEYNOTE-890 studies and, to a lesser extent, our other ongoing clinical trials and studies, and to continue our research and development activities for our next-generation electroporation device and drug discovery efforts. In addition, we expect to pursue capital-raising transactions, which could include equity or debt financings, in the near term to fund our existing and planned operations and acquire and develop additional assets and technology consistent with our business objectives as opportunities arise.

We currently estimate our monthly working capital requirements to be approximately \$2.1 million, although we may modify or deviate from this estimate and it is likely that our actual operating expenses and working capital requirements will vary from our estimate. Based on these expectations regarding future expenses, rate of consumption, as well as our current cash levels, we believe our cash resources are sufficient to meet our anticipated needs for more than the 12 months following the issuance of this report. We will continue to assess our cash resources and anticipated needs on a quarterly basis.

Sources of Capital

We have not generated any revenue since our inception, and we do not anticipate generating meaningful, or any, revenue in the near term. Historically, we have raised the majority of the funding for our business through offerings of our common stock and warrants to purchase our common stock. If we issue equity or convertible debt securities to raise additional funds, our existing stockholders would experience further dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. If we incur debt, our fixed payment obligations, liabilities and leverage relative to our equity capitalization would increase, which could increase the cost of future capital. Further, the terms of any debt securities we issue or borrowings we incur, if available, could impose significant restrictions on our operations, such as limitations on our ability to incur additional debt or issue additional equity or other operating restrictions that could adversely affect our ability to conduct our business, and any such debt could be secured by any or all of our assets pledged as collateral. Additionally, we may incur substantial costs in pursuing future capital, including investment banking, legal and accounting fees, printing and distribution expenses and other costs.

Moreover, equity or debt financings or any other source of capital may not be available to us when needed or at all, or, if available, may not be available on commercially reasonable terms. Weak economic and capital market conditions generally or uncertain conditions in our industry could increase the challenges we face in raising capital for our operations. In recent periods, the capital and financial markets for early and development-stage biotechnology and life science company stocks have been volatile and uncertain. If we cannot raise the funds that we need, we could be forced to delay or scale down some or all of our development activities or cease all operations, and our stockholders could lose all of their investment in our Company.

Alpha Holdings

On August 31, 2018, the Company entered into a stock purchase agreement with Alpha Holdings, Inc. (“Alpha Holdings”), pursuant to which the Company agreed to issue and sell to Alpha Holdings shares of its common stock equal to an aggregate amount of up to \$15.0 million at a market purchase price of \$1.50 per share, which was the closing price of the Company’s common stock the day immediately before the agreement was executed by the parties.

On October 9, 2018, the Company received total proceeds, before expenses, of \$8.0 million in cash from the offering and issued Alpha Holdings 5,333,333 shares of common stock at a purchase price of \$1.50 per share. On December 6, 2018, the Company received total proceeds, before expenses, of \$7.0 million in cash from the offering and issued Alpha Holdings 4,666,667 shares of common stock at a purchase price of \$1.50 per share. There were no underwriting or placement agent fees associated with the offering.

Common Stock Option Exercise

During the six months ended January 31, 2019, shares of common stock issued related to option exercises totaled 430,293. The Company realized proceeds of \$0.6 million from the stock option exercises.

Controlled Equity Offering Sales Agreement

On November 2, 2018, the Company entered into a Sales Agreement with Cantor Fitzgerald & Co. regarding an at-the-market offering, pursuant to which the Company may, from time to time, issue and sell shares of common stock having an aggregate offering price of up to \$30.0 million. The Company is not obligated to make any sales of shares under the Sales Agreement. To date, the Company has not made any sales of shares under the Sales Agreement.

Critical Accounting Policies

Investment Securities

Securities held to maturity are recorded at amortized cost based on the Company's positive intent and ability to hold these securities to maturity.

Management evaluates whether securities held to maturity are other-than-temporarily impaired ("OTTI") on a quarterly basis. Debt securities with unrealized losses are considered OTTI if the Company intends to sell the security or if it is more likely than not that the Company will be required to sell such security prior to any anticipated recovery. If management determines that a security is OTTI under these circumstances, the impairment recognized in earnings is measured as the entire difference between the amortized cost and the then-current fair value.

Accounting for Long-Lived Assets

We assess the impairment of long-lived assets, consisting of property and equipment, periodically and whenever events or circumstances indicate that the carrying value may not be recoverable. Examples of such circumstances may include: (1) the asset's ability to continue to generate income from operations and positive cash flow in future periods; (2) loss of legal ownership or title to an asset; (3) significant changes in our strategic business objectives and utilization of the assets; and (4) the impact of significant negative industry or economic trends. If a change were to occur in any of these or similar factors, the likelihood of a material change in our net loss would increase.

Recoverability of assets to be held and used in operations is measured by a comparison of the carrying amount of an asset to the future net cash flows expected to be generated by the assets. Although we believe the factors used by management to evaluate future net cash flows are reasonable, this evaluation requires a high degree of judgment, and results could vary if the actual amounts are materially different than management's estimates. In addition, we base estimates of useful lives and related amortization or depreciation expense on our subjective estimate of the period the assets will generate revenue or otherwise be used by us. If long-lived assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less selling costs.

Equity-Based Awards

The Company grants equity-based awards (typically stock options or restricted stock units) under our stock-based compensation plan and outside of our stock-based compensation plan, with terms generally similar to the terms under our stock-based compensation plan. The Company estimates the fair value of stock option awards using the Black-Scholes option valuation model. For employees, directors and consultants, the fair value of the award is measured on the grant date. Prior to the adoption of ASU 2018-07 on August 1, 2018, the fair value of the award for non-employees was generally re-measured on vesting dates and interim financial reporting dates until the service period was complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. The Company estimates the fair value of restricted stock unit awards based on the closing price of the Company's common stock on the date of issuance. Changes in assumptions used under the Black-Scholes option valuation model could materially affect the Company's net loss and net loss per share.

Employee Stock Purchase Plan

Employees may elect to participate in our stockholder approved employee stock purchase plan. The stock purchase plan allows for the purchase of our common stock at not less than 85% of the lesser of (i) the fair market value of a share of stock on the beginning date of the offering period or (ii) the fair market value of a share of stock on the purchase date of the offering period, subject to a share and dollar limit as defined in the plan and subject to the applicable legal requirements. There are two 6-month offering periods during each fiscal year, ending on January 31 and July 31. In accordance with applicable accounting guidance, the fair value of awards under the stock purchase plan is calculated at the beginning of each offering period. We estimate the fair value of the awards using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and the offering period. This fair value is then amortized at the beginning of the offering period. Stock-based compensation expense is based on awards expected to be purchased at the beginning of the offering period, and therefore is reduced when participants withdraw during the offering period.

Australia Research and Development Tax Credit

Our Australian, wholly-owned, subsidiary incurs research and development expenses, primarily in the course of conducting clinical trials. The Australian research and development activities qualify for the Australian government's tax credit program, which provides a 41.0 percent credit for qualifying research and development expenses. The tax credit does not depend on our generation of future taxable income or ongoing tax status or position. Accordingly, the credit is not considered an element of income tax accounting under ASC 740 and is recorded against qualifying

research and development expenses in the Condensed Consolidated Statements of Operations.

Tax Reform

The Tax Cuts and Jobs Act was signed into law in December 2017, impacting federal corporate tax rates. While the Act will impact certain aspects in the calculation of our tax provision, we maintain a full valuation allowance and the effects of the 2017 Tax Act did not have a significant impact on the Company's unaudited condensed consolidated financial statements for the three and six months ended January 31, 2019.

Recent Accounting Pronouncements

Information regarding recent accounting pronouncements is contained in Note 2 to our condensed consolidated financial statements included in this report.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditure or capital resources that is material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, or Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, or the SEC, and that such information is accumulated and communicated to our management, including our President and Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer), as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures reflects the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

As required by Rule 13a-15(b) under the Exchange Act, our management, under the supervision and with the participation of our President and Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of January 31, 2019. Based on such evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of January 31, 2019, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during our fiscal quarter ended January 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls

Our management, including our President and Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

In the ordinary course of business, we may become a party to lawsuits involving various matters. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently a party, and our properties are not currently subject, to any legal proceedings that, in the opinion of management, are expected to have a material adverse effect on our business, financial condition or results of operations.

ITEM 1A. RISK FACTORS.

There have been no material changes to the Risk Factors in Item 1A of our Annual Report on Form 10-K for the fiscal year ended July 31, 2018.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

From November 1, 2018 to January 1, 2019, we issued a total of 90,000 shares of our common stock to a third-party firm pursuant to a consulting agreement at an average market price of \$1.14 per share for services rendered.

From November 1, 2018 to January 1, 2019, we issued a total of 33,000 shares of our common stock to a third-party firm pursuant to a consulting agreement at an average market price of \$1.14 per share for services rendered.

On December 12, 2018, we issued 20,000 shares of our common stock to a third-party firm pursuant to a consulting agreement at a market price of \$0.814 per share for services rendered.

On November 21, 2018, we issued a total of 250,000 common stock options with an exercise price of \$0.85 per share to a third-party consultant pursuant to a consulting agreement.

The securities above were offered and sold without registration under the Securities Act of 1933, as amended, or the Securities Act, pursuant to the exemption provided in Section 4(a)(2) under the Securities Act as a transaction not involving a public offering as well as similar exemptions under applicable state laws, in reliance on the following facts: no general solicitation was used in the offer or sale of such shares; the recipient of such shares represented that it was acquiring the shares for investment for its own account and not with a view to or for resale in connection with any distribution thereof within the meaning of the Securities Act; the recipient of such shares had adequate access to information about us; the recipient of such shares represented that it had a preexisting business or personal relationship with us or had the capacity to protect its own interests in connection with acquiring such shares; and such shares were issued as restricted securities with restricted legends referring to the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

None.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

The following exhibits are either filed or furnished with this report:

- 31.1 Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934
- 31.2 Certification of Chief Financial Officer pursuant to Rules 13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934
- 32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 101.INS XBRL Instant Document
- 101.SCH XBRL Taxonomy Extension Schema Document
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document
- 101.LAB XBRL Taxonomy Extension Label Linkbase Document
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ONCOSEC MEDICAL INCORPORATED

By: */s/ Daniel J. O'Connor*

Daniel J. O'Connor

President & Chief Executive Officer

(Principal Executive Officer)

Dated: March 8, 2019

By: */s/ Sara M. Bonstein*

Sara Bonstein

Chief Financial Officer & Chief Operating Officer

(Principal Financial Officer)

Dated: March 8, 2019

